The maintenance of a Neutral rating and a $1.25 price target by B. Riley Securities indicates no significant change in the analyst's view on Rigel Pharmaceuticals. This suggests that the analyst sees the company's prospects as stable, without any new positive or negative information to significantly alter the stock's valuation in the short term.